Locally Advanced or Metastatic Solid Tumors research hub
8 indexed studies · 5 currently recruiting
- recruitingPHASE1
Study of XB010 in Subjects With Solid Tumors
This study is testing a new medicine called XB010, both on its own and with another drug (pembrolizumab), for people with certain advanced solid cancers. It aims to see how safe it is, how well the body handles it, and if it helps shrink tumours when other treatments haven't worked.
United States · United Kingdom - recruitingPHASE1
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
This study is testing a new medicine called MOv18 IgE for women with advanced ovarian, endometrial, or triple-negative breast cancer. It aims to find a safe dose and see how well it works, especially in cancers that have a specific marker called Folate Receptor Alpha.
United Kingdom - recruitingPHASE1, PHASE2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
This study is looking at a new drug, GTAEXS617, for people with advanced solid tumours, including certain types of breast, lung, head and neck, and ovarian cancers. We want to see how safe it is, how the body handles it, and if it can shrink tumours.
United States · Belgium · United Kingdom - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
This study looks at a new way to treat an aggressive type of breast cancer called Triple Negative Breast Cancer (TNBC). It combines a special immune-boosting drug (Pembrolizumab) with standard chemotherapy to see if it can shrink tumours more effectively before surgery and prevent them from returning.
Portugal · Germany · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
This study is testing a new combination of medicines for people with a type of breast cancer called triple-negative breast cancer that has spread or can't be removed with surgery. It aims to see if the new combination can help people live longer without their cancer getting worse.
Czechia · Hungary · Poland - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
This study is testing a new medicine, BMS-986288, alone and with another drug, nivolumab. It's for people with various advanced cancers. The main goals are to check for side effects and how well the new medicine works against the cancer.
Spain · France · Italy - recruitingPHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
This study looks at new treatments for triple negative breast cancer that hasn't fully responded to initial chemotherapy. We're testing if medicines, given briefly before surgery, can start to shrink the cancer or change it in helpful ways.
United Kingdom